Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation

The aim of the trial was to assess whether extending plasma levels of the alpha7-nicotinic acetylcholine receptor (nAChR) agonist 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) over time enhances its cognitive effects in schizophrenia. Both smoking and non-smoking patients were studied, to determi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuropsychopharmacology
Autores principales: Kem, William R, Olincy, Ann, Johnson, Lynn, Harris, Josette, Wagner, Brandie D, Buchanan, Robert W, Christians, Uwe, Freedman, Robert
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5770760/
https://ncbi.nlm.nih.gov/pubmed/28825423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2017.182
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares